Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

Simple Summary Since the identification of a large variety of biomarkers in B cell
malignancies as being driving factors for tumor progression and patient prognosis, their …

This registration study assessed clinical outcomes of TQ-B3525, the dual
phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular …

T-lymphocytes are prevalent in the tumor microenvironment of follicular lymphoma (FL).
However, the phenotype of T-cells may vary, and the prevalence of certain T-cell subsets …

Immunomodulatory agent lenalidomide is effective in treating follicular lymphoma (FL). We
conducted the first trial of immunotherapy rituximab plus lenalidomide in newly diagnosed …

The multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419)
explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus …

According to the latest epidemiology of the US, B-cell cancers account for> 3% of all new
cancer cases and> 80% of non-Hodgkin lymphomas. However, the disease-modifying small …

Patients with follicular lymphoma, an indolent form of non-Hodgkin lymphoma, typically
experience multiple relapses over their disease course. Periods of remission become …

Follicular lymphoma (FL) is the most common indolent lymphoma originating from germinal
center B cells. FL represents a clinically and biologically heterogeneous disease. Most …

Purpose The prognostic value of interim 18F-FDG PET/CT (I-PET) for follicular lymphoma
(FL) is controversial, and may be related to the lack of strict standards in terms of age …